Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.31 |
| ▸ | MGLL | Q99685 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13464052 | 0.90 | MEN1 (0.37) | TSHR | |
| SCHEMBL13464062 | 0.90 | MEN1 (0.37) | TSHR | |
| SCHEMBL18755724 | 0.89 | ALOX12 (0.33) | ALOX12 | |
| SCHEMBL11998879 | 0.87 | ALOX12 (0.35) | ALOX12 | |
| SCHEMBL23608353 | 0.87 | ALOX12 (0.30) | ALOX12MGLL | |
| SCHEMBL11989407 | 0.85 | ALDH1A1 (0.32) | TSHRALOX12MGLL | |
| SCHEMBL29842557 | 0.85 | ALDH1A1 (0.32) | TSHRALOX12MGLL | |
| SCHEMBL1949595 | 0.85 | ALOX12 (0.38) | TSHRALOX12MGLL | |
| SCHEMBL13748507 | 0.85 | ALOX12 (0.38) | TSHRALOX12MGLL | |
| Ethylene Glycol SCHEMBL8522385 | 0.84 | MGLL (0.33) | ALOX12MGLL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 228 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240238480-A1 | DEVICES FOR IN SITU FORMED NERVE CAPS AND/OR NERVE WRAPS | TULAVI THERAPEUTICS INC (US) | 2024-07-18 | — | — | US | claimed |
| CN-118105543-A | Vancomycin-carrying hydrogel porous surgical implant for treating infectious bone defect and preparation method thereof | 山东大学齐鲁医院 | 2024-05-31 | — | — | CN | claimed |
| US-11944717-B2 | Devices for in situ formed nerve caps and/or nerve wraps | Tulavi Therapeutics, Inc. (US) | 2024-04-02 | — | — | US | claimed |
| CN-112638437-B | Method and apparatus for forming nerve caps in situ | 图拉维治疗股份有限公司 | 2023-12-08 | — | — | CN | claimed |
| CN-115361912-A | Method and apparatus for in situ formation of a nerve cap with quick release | 图拉维治疗股份有限公司 | 2022-11-18 | — | — | CN | claimed |
| US-20220054705-A1 | DEVICES FOR IN SITU FORMED NERVE CAPS AND/OR NERVE WRAPS | Tulavi Therapeutics, Inc. | 2022-02-24 | — | — | US | claimed |
| CN-110251731-B | Islet cell microcapsule for tissue engineering and preparation method thereof | 山东百多安医疗器械股份有限公司 | 2021-09-03 | — | — | CN | claimed |
| CN-110201234-B | Prostate cell microcapsule for tissue engineering and preparation method thereof | 山东百多安医疗器械股份有限公司 | 2021-09-03 | — | — | CN | claimed |
| WO-2021146330-A1 | METHODS AND DEVICES FOR IN SITU FORMED NERVE CAP WITH RAPID RELEASE | Tulavi Therapeutics, Inc. (US) | 2021-07-22 | — | — | WO | claimed |
| CN-112638437-A | Method and apparatus for forming a nerve cap in situ | 图拉维治疗股份有限公司 | 2021-04-09 | — | — | CN | claimed |
| EP-0994959-A1 | POLYMER-MODIFIED VIRUSES | GENZYME CORPORATION (US) | 2000-04-26 | — | — | EP | claimed |
| WO-2000011202-A1 | CATIONIC COMPLEXES OF POLYMER-MODIFIED ADENOVIRUS | GENZYME CORPORATION (US) | 2000-03-02 | — | — | WO | claimed |
| JP-2907300-B2 | — | — | 1999-06-21 | — | — | JP | claimed |
| WO-1998044143-A9 | POLYMER-MODIFIED VIRUSES | GENZYME CORP (US) | 1999-04-22 | — | — | WO | claimed |
| WO-1998044143-A1 | POLYMER-MODIFIED VIRUSES | GENZYME CORPORATION (US) | 1998-10-08 | — | — | WO | claimed |
| US-5620884-A | MODIFIED POLYETHER | ENZON, INC. (US) | 1997-04-15 | — | — | US | claimed |
| US-5386014-A | Reducing and deoxygenating bovine hemoglobin; conjugation to activated polyalkylene oxide in presence of chloride anions | ENZON, INC. (US) | 1995-01-31 | — | — | US | claimed |
| EP-0502113-A4 | CHEMICALLY MODIFIED HEMOGLOBIN AS AN EFFECTIVE, STABLE, NON-IMMUNOGENIC RED BLOOD CELL SUBSTITUTE | — | 1993-03-31 | — | — | EP | claimed |
| EP-0502113-A1 | CHEMICALLY MODIFIED HEMOGLOBIN AS AN EFFECTIVE, STABLE, NON-IMMUNOGENIC RED BLOOD CELL SUBSTITUTE | ENZON, INC. (US) | 1992-09-09 | — | — | EP | claimed |
| WO-1991007190-A1 | CHEMICALLY MODIFIED HEMOGLOBIN AS AN EFFECTIVE, STABLE, NON-IMMUNOGENIC RED BLOOD CELL SUBSTITUTE | ENZON, INC. (US) | 1991-05-30 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11944717-B2 | Devices for in situ formed nerve caps and/or nerve wraps | GAP43, NGF, CAPG | TSHR 3914/4885ALOX12 4051/4885MGLL 2639/4885 |
| US-20240238480-A1 | DEVICES FOR IN SITU FORMED NERVE CAPS AND/OR NERVE WRAPS | GAP43, NGF, CAPG | TSHR 3914/4885ALOX12 4051/4885MGLL 2639/4885 |
| US-20220054705-A1 | DEVICES FOR IN SITU FORMED NERVE CAPS AND/OR NERVE WRAPS | GAP43, NGF, CAPG | TSHR 3901/4885ALOX12 4047/4885MGLL 2629/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.